Status:
COMPLETED
PRION-1: Quinacrine for Human Prion Disease
Lead Sponsor:
Medical Research Council
Conditions:
Prion Disease
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in human prion disease. It also aims to establish an appropriate framework for the clinical assessment of therape...
Detailed Description
The human prion diseases have been traditionally classified into Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker (GSS) disease and kuru. They can alternatively be classified into three...
Eligibility Criteria
Inclusion
- Aged 12 years or more, diagnosed with any type of human prion disease.
Exclusion
- In a coma, or in a pre-terminal phase of disease such that prolongation of the current quality of life would not be supported
- Known sensitivity to quinacrine
- Been taking any other putative anti-prion therapy for less than 8 weeks
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00104663
Start Date
June 1 2004
End Date
March 1 2007
Last Update
April 7 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Prion Clinic
London, United Kingdom, WC1N 3BG